Last week, the food and drugs (FDA) revocation Avastin for treating late stage metastatic breast cancer drug regulatory approval. Each year, chosen by American women 17,500 practicing oncologists to save them from their mortal, cancer strongly progressed to prescribe Avastin to treat them.
FDA explained that it was revoking the approval of the drug use because it decided that the drug does not provide "a benefit enough in slowing the progression of the disease to compensate for the significant
Subscribe to:
Post Comments (Atom)
Post a Comment